CJC-1295 with DAC

What it is

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting GHRH analog developed by ConjuChem in the early 2000s. It contains the same modified GHRH 1-29 sequence as CJC-1295 (no DAC), with an additional lysine-maleimidopropionic acid moiety that covalently binds to circulating albumin in vivo. This albumin binding extends the half-life dramatically — to approximately 8 days, compared to ~30 minutes for the no-DAC version.

The extended half-life of CJC-1295 with DAC produces a fundamentally different pharmacological profile from CJC-1295 (no DAC) and from physiologic GHRH signaling. Rather than amplifying pulsatile GH release, CJC-1295 with DAC produces continuous elevation of GH/IGF-1 levels — more similar to recombinant growth hormone administration than to natural GHRH function.

Mechanism of action

The mechanism is the same as other GHRH analogs at the receptor level: binding the pituitary GHRH receptor and stimulating GH release. The clinically relevant difference is the duration of receptor stimulation:

• CJC-1295 (no DAC): short pulses of receptor stimulation that preserve pulsatile GH release patterns
• CJC-1295 with DAC: continuous receptor stimulation over many days, producing sustained GH/IGF-1 elevation that bypasses the pulsatile pattern of natural physiology

This mechanistic difference has clinical implications. Pulsatile GH release is associated with the beneficial effects of GH on body composition, sleep, and recovery without producing the metabolic and physical features of acromegaly. Continuous GH elevation (as can occur with exogenous GH or with CJC-1295 with DAC) more closely approximates the pathological state of acromegaly and may carry different long-term risks.

Clinical evidence

Early-phase clinical trials by ConjuChem in the mid-2000s established the pharmacology of CJC-1295 with DAC and demonstrated sustained IGF-1 elevation with weekly dosing. The clinical development program was eventually discontinued, partly due to a serious adverse event (cardiac arrest) in one trial participant — though this event was not definitively linked to the drug.

The ConjuChem trial data is the primary clinical evidence base for CJC-1295 with DAC. Subsequent clinical use has been entirely off-label and through compounding pharmacies, without large-scale validation in formal trials.

Why we don’t prescribe it at The Tide

We strongly prefer CJC-1295 (no DAC) over CJC-1295 with DAC for adult GH-axis support, for several reasons:

• Preservation of pulsatile GH release: the pulsatile pattern is biologically important and is preserved with the no-DAC version but disrupted with the DAC version
• Safety profile: the no-DAC version more closely approximates physiology, with theoretically lower risk of acromegaly-like effects from sustained GH elevation
• Adjustability: the short half-life of the no-DAC version allows dose adjustments and discontinuation without prolonged effects from accumulated drug
• The 2007 cardiovascular event: while not definitively drug-related, the event in the ConjuChem trial program is notable and has informed our preference for the safer no-DAC alternative

Patients seeking GH-axis support are better served by CJC-1295 (no DAC) + ipamorelin or sermorelin protocols, which preserve physiologic pulsatility while providing meaningful clinical benefit.

Side effects and contraindications

The side effect profile of sustained-elevated GH/IGF-1 includes joint discomfort, water retention, paresthesias, glucose intolerance, and theoretical concerns about long-term acromegaly-like effects. Same contraindications as other GH-axis stimulants: malignancy, pregnancy, pituitary disease, severe diabetes, severe obesity.